Skip to content

Partnerships

It’s the partnerships that make the difference. At Ultromics, we are committed to building working relationships throughout the health, pharmaceutical, and government sectors as we fight against heart failure.

Why Ultromics is Working with Leaders to Revolutionize the Fight Against Heart Failure 

 

 

Overcoming the heart failure epidemic is a complex challenge that requires a collective effort. 

Our experience partnering with healthcare professionals, patients, regulators, and technology companies has already led to game-changing solutions, but this is just the beginning. 

The more we collaborate, the more we learn from one another. It’s time to combine our knowledge and resources to make a meaningful impact in the fight against heart failure.

Our Partnership Goals are to: 

  • Help achieve faster and more precise heart failure diagnoses that will improve patient outcomes
  • Widen our existing knowledge base and increase our expertise on heart failure
  • Continue to speed up AI innovation and scale up our platform
  • Maintain our close connections within the global scientific community
  • Increase inter-industry and academic-industry collaborations.

Our Partnership Goals are to: 



  • Help achieve faster and more precise heart failure diagnoses that will improve patient outcomes 
  • Widen our existing knowledge base and increase our expertise on heart failure
  • Continue to speed up AI innovation and scale up our platforms

 



  • Maintain our close connections within the global scientific community
  • Increase inter-industry and academic-industry collaborations

Types of Partnerships

Health Systems & Private Practices

We have strong partnerships with health organizations, institutions, private practices, and resource centers that deliver healthcare services to their local communities, especially those focusing on finding more precise methods for identifying patients with heart failure.  

Some of our current partners include Mayo Clinic, Northwestern, Oregon Health and Science University (OHSU), the University of Textas Southwestern, and the University of Chicago. 

Find out more

Government & Associations

Our experience with global associations and key government bodies with stakes in the medical industry has shown us how powerful these partnerships are. Combining our technology with the vast knowledge available through medical associations and public sector organizations can significantly improve the delivery of rapid and precise heart failure diagnoses to patients on a global scale. 

We are currently partnering with the Foundation for the National Instututes of Health (FNIH) as part of the The Accelerating Medicines Partnership® Heart Failure (AMP® HF). We’re also a proud industry round table partner of the American Society of Echocardiography (ASE). 

Find out more

Pharmaceutical

The pharmaceutical sector plays a crucial role in novel approaches that enable early detection of heart failure. We’re thrilled to partner with innovative companies that are on the cutting edge of heart failure treatment, especially heart failure with preserved ejection fraction (HFpEF). 

We are especially proud of our partnership with Janssen Pharmaceuticals, who is as committed to making a difference in the lives of heart failure patients as we are. 

Find out more
<br>

What we have achieved with our Partnerships

Published research and validation

Through our partnerships with Mayo Clinic, Janssen, and the NHS, we have trained and tested our technology to ensure trust for providers. This technology has gone on to be peer-reviewed in JACC and JASE.

 

Reliability in the heart failure sector

With our partners’ continuous support, our technology has proven its reliability through commercial clearances, including three FDA clearances, two CE marks, and two FDA breakthrough designations.

Access to world-leading science and data

Through our partnerships with Mayo Clinic, Janssen, and the NHS, we have trained and tested our technology to ensure trust for providers. This technology has gone on to be peer-reviewed in JACC and JASE.

 

Building a community of medical and tech experts

Through our partnerships with Mayo Clinic, Janssen, and the NHS, we have trained and tested our technology to ensure trust for providers. This technology has gone on to be peer-reviewed in JACC and JASE.

 

Partnerships and Customers

“We are pleased to welcome Ultromics to the Microsoft Azure Marketplace. Healthcare providers are looking for solutions that are trusted, secure and simple to deploy that come fully managed with 24/7 support. EchoGo is a secure solution enabling hospitals to take their workforce analysis off-site, via the Microsoft Azure cloud.”

David Houlding , Director of Healthcare Experiences at Microsoft.

What We Have Achieved with our Partnerships

Published Research and Validation

Through our partnerships with Mayo Clinic, Janssen, and the NHS, we have trained and tested our technology to ensure trust for providers. This technology has gone on to be peer-reviewed in JACC and JASE. 

Reliability in the heart failure sector

With our partners’ continuous support, our technology has proven its reliability through commercial clearances, including three FDA clearances, two CE marks, and two FDA breakthrough designations. 

Access to world-leading science and data

Our technology was built on ten years of outcome data. We were born out of Oxford University from leading minds in science and built in partnership with the U.K.’s National Health Service (NHS).  

We are committed to ongoing partnerships with leading organizations as we seek to achieve continuous improvement of our unparalleled AI technology. 

Building a community of medical and tech experts

We have brought together some of the world’s top experts in both medical science and AI technology to maximize the application of our groundbreaking platform. We’ve built a world-leading Scientific Advisory Board with key industry experts from Northwestern Medicine, Baylor Scott & White, Mayo Clinic, and Harvard Medical Center.

Heart Failure Looking for Partnerships?   We'd like to hear from you and your interest in improving the diagnosis and treatment of heart failure.   

 

What others say about our partnerships:



After Ultromics joined as a full partner The Accelerating Medicines Partnership® Heart Failure (AMP® HF), which includes the National Heart Lung and Blood Institute (NHLBI): 

What others say about our partnerships:

After Ultromics joined as a full partner The Accelerating Medicines Partnership® Heart Failure (AMP® HF), which includes the National Heart Lung and Blood Institute (NHLBI): 

 

“The AMP Heart Failure program—and the high caliber of the partnership at its core—will help us better understand and treat [heart failure] with the goal of ultimately benefiting millions”

Dr. Gary H. Gibbons , NHLBI Director

A powerful history of collaboration

2017: Spun out of the University of Oxford
2018: Secured a £10M Series-A investment to develop AI for heart disease. The funding was lead by Oxford Sciences Innovation (OSI).
2019: Secures FDA clearance and a CE mark for AI that automates LV analysis.
2020: Partners with the Mayo Clinic on a research program to use AI to improve heart failure detection.
2020: Partners with Microsoft Azure Marketplace allowing hospitals to use and connect Ultromics via the cloud.
2021: Joins the American Society of Echocardiography (ASE) Industry Roundtable partnership.
2021: Partners with Janssen Biotech Inc. part of Johnson & Johnson, on a project to improve cardiac amyloidosis detection.
2022: Key partner in the World Alliance Societies of Echocardiography (WASE), led by the American Society of Echocardiography (ASE), using AI in the COVID-19 pandemic.
2022: Secures $33 million in a Series B funding roundled by the Blue Venture Fund with participationfrom Optum Ventures, Google Ventures, andexisting investor Oxford Sciences Innovation.
2022: Partners with the Foundation for the National Institutes of Health (FNIH) in their AcceleratingMedicines Partnership® Heart Failure (AMP®HF). A five-year, $37 million multi-stakeholder collaboration investigating HFpEF.
2023 Works alongside The Centers for Medicare and Medicaid Services (CMS) to assign a new Healthcare Common Procedure Coding System(HCPCS) Code C9786 when using Ultromics technology.
2023: Secures FDA breakthrough device designation for AI that can detect cardiac amyloidosis.

Investors

Our investors have served as the backbone of our advances in AI for heart failure detection. They have enabled us to create and implement a groundbreaking, FDA-approved AI platform built on over ten years of known outcomes.

Listed below are just a few of our investors so far:

Connecting our Technology

We partner with tech leaders to offer seamless and secure ways to connect our technology. This is why Ultromics was thrilled to work with Microsoft to implement its AI service on the Microsoft Azure Marketplace. This online store provides certified software applications and services for use on Microsoft Azure, and the availability of EchoGo in the Microsoft Azure Marketplace created a streamlined way for hospitals to connect EchoGo with industry-leading capabilities

Looking for partnerships?

We'd like to hear from you and about your interest in improving the diagnosis and treatment of heart failure. 

Contact Us